videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

Embla Medical

Embla Medical will release its Q2 2025 interim report on 22 July 2025. On the same day at 11:00 CEST, the company’s management will present the results and answer questions during a live online event.


You can already now sign up for the event and send in your questions. You don&#x2019;t have to participate live to submit questions for the event. Embla Medical will release its Q2 2025 interim report on 22 July 2025. On the same day at 11:00 CEST, the company&#x2019;s management will present the results and answer questions during a live online event. Embla Medical&#x2019;s Q1 2025 results showed a reasonably start to the year, with 4% organic growth and signs of stronger momentum toward the end of the quarter. Growth was driven by the Prosthetics &amp; Neuro Orthotics business segment and, regionally, by the APAC and EMEA markets. The Patient Care segment and the US market lagged behind. EBITDA margins improved by 1 percentage point compared to the same period last year, reaching 18.1%. Although growth for the quarter came in below the full-year guidance range, the company reaffirmed its 2025 outlook, expecting organic growth of 5&#x2013;8% and an EBITDA margin of 20&#x2013;21%. The company stated that the 2025 financial guidance includes the impact of already implemented U.S. trade tariffs, though it is too speculative at this stage to quantify the exact effect. Management expects to mitigate some of the potential short-term impact and to adjust the supply chain in the medium to long term to largely offset the effect. In addition to the Q2 2025 financial results and how they track against full-year guidance, focus may also be directed toward updates on the commercial traction of the newly launched Navii and Icon bionic knees, further developments regarding tariff impacts, and whether momentum has returned in the US market. Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. The company enhances people&#x2019;s mobility through the development and delivery of Prosthetics &amp; Neuro Orthotics, Bracing &amp; Supports, and Patient Care. Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 13.28, 17-06-2025.

Embla Medical – Presentation of Q2 2025 Interim Report

Recent videos